Press release
Intrahepatic Cholangiocarcinoma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Intrahepatic Cholangiocarcinoma Overview
Cancer that occurs in the parts of the bile ducts that are within the liver is called intrahepatic cholangiocarcinoma (ICC), also known as intrahepatic bile duct cancer. ICC is a rare disease and makes up about 10% of all Cholangiocarcinoma.
"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report: https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as - Xencor, Inc., Relay Therapeutics, Forma Therapeutics, Inc., Kinnate Biopharma, TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd, Basilea Pharmaceutical, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment
• Intrahepatic Cholangiocarcinoma Emerging therapies such as - XmAb®22841, RLY-4008, FT-2102, KIN-3248, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.
• ,Basilea Pharmaceutical initiated a Phase 1/2 Study of ARQ 087 in AdultSubjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic CholangiocarcinomaWith FGFR2 Gene Fusion.
• Derazantinib has demonstrated antitumor activity and a manageable safety profile in a previous biomarker-driven phase 1/2 study in iCCA patients,10 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting three clinical studies with derazantinib.
Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment
• Intrahepatic Cholangiocarcinoma Assessment by Product Type
• Intrahepatic Cholangiocarcinoma By Stage and Product Type
• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
• Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
• Intrahepatic Cholangiocarcinoma by Stage and Molecule Type
DelveInsight's Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:
• XmAb®22841: Xencor, Inc.
• RLY-4008: Relay Therapeutics
• FT-2102: Forma Therapeutics, Inc.
• KIN-3248: Kinnate Biopharma
• SD 101: TriSalus Life Sciences
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
• VG161: Virogin Biotech Ltd
• Derazantinib: Basilea Pharmaceutical
Intrahepatic Cholangiocarcinoma Pipeline Analysis:
The Intrahepatic Cholangiocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Intrahepatic Cholangiocarcinoma treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
• Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies at:
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Intrahepatic Cholangiocarcinoma Pipeline Market Drivers
• Rising incidence of Cholangiocarcinoma. ICC makes up 8-10% of all Cholangiocarcinoma
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma Pipeline Market Barriers
• Poor prognosis and diagnosis of the disease
• Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication.
Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Assessment- https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Forma Therapeutics, Inc., Kinnate Biopharma, TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd, Basilea Pharmaceutical, and others
• Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, FT-2102, KIN-3248, SD 101, Camrelizumab, VG161, Derazantinib, and others
• Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
• Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers
Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Intrahepatic Cholangiocarcinoma Report Introduction
2 Intrahepatic Cholangiocarcinoma Executive Summary
3 Intrahepatic Cholangiocarcinoma Overview
4 Intrahepatic Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment
5 Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
6 Intrahepatic Cholangiocarcinoma Late Stage Products (Phase II/III)
7 Intrahepatic Cholangiocarcinoma Mid Stage Products (Phase II)
8 Intrahepatic Cholangiocarcinoma Early Stage Products (Phase I)
9 Intrahepatic Cholangiocarcinoma Preclinical Stage Products
10 Intrahepatic Cholangiocarcinoma Therapeutics Assessment
11 Intrahepatic Cholangiocarcinoma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Intrahepatic Cholangiocarcinoma Key Companies
14 Intrahepatic Cholangiocarcinoma Key Products
15 Intrahepatic Cholangiocarcinoma Unmet Needs
16 Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
17 Intrahepatic Cholangiocarcinoma Future Perspectives and Conclusion
18 Intrahepatic Cholangiocarcinoma Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies- https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Intrahepatic Cholangiocarcinoma Market https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Intrahepatic Cholangiocarcinoma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Intrahepatic Cholangiocarcinoma Epidemiology https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Intrahepatic Cholangiocarcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2842162 • Views: …
More Releases from DelveInsight Business Research
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain.
Explore the…
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field.
Stay informed with the latest developments! Access…
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP…
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma…
